These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

8442 related items for PubMed ID: 23373092

  • 1. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [Abstract] [Full Text] [Related]

  • 2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [Abstract] [Full Text] [Related]

  • 3. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC, Matalka MS.
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [Abstract] [Full Text] [Related]

  • 4. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM, Lyseng-Williamson KA.
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [Abstract] [Full Text] [Related]

  • 5. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM.
    BioDrugs; 2012 Oct 01; 26(5):325-34. PubMed ID: 22946753
    [Abstract] [Full Text] [Related]

  • 6. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL, Lopez IE, Desai SR.
    J Drugs Dermatol; 2015 May 01; 14(5):509-10. PubMed ID: 25942671
    [Abstract] [Full Text] [Related]

  • 7. Vemurafenib in melanoma.
    Shaw HM, Nathan PD.
    Expert Rev Anticancer Ther; 2013 May 01; 13(5):513-22. PubMed ID: 23617343
    [Abstract] [Full Text] [Related]

  • 8. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
    Patrawala S, Puzanov I.
    Future Oncol; 2012 May 01; 8(5):509-23. PubMed ID: 22646766
    [Abstract] [Full Text] [Related]

  • 9. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A, Cohen MS.
    Expert Opin Drug Discov; 2016 Sep 01; 11(9):907-16. PubMed ID: 27327499
    [Abstract] [Full Text] [Related]

  • 10. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C, How-Kit A, Battistella M, Sadoux A, Podgorniak MP, Sidina I, Pages C, Roux J, Porcher R, Tost J, Mourah S.
    Melanoma Res; 2014 Aug 01; 24(4):415-8. PubMed ID: 24933605
    [No Abstract] [Full Text] [Related]

  • 11. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
    Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.
    Clin Cancer Res; 2014 Oct 01; 20(19):4994-5000. PubMed ID: 25096067
    [Abstract] [Full Text] [Related]

  • 12. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN, Singh M, Tiwari U, Hutchins LF.
    J Postgrad Med; 2014 Oct 01; 60(2):187-8. PubMed ID: 24823520
    [Abstract] [Full Text] [Related]

  • 13. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group.
    N Engl J Med; 2011 Jun 30; 364(26):2507-16. PubMed ID: 21639808
    [Abstract] [Full Text] [Related]

  • 14. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JH, Giuliani R, Pignatti F.
    Eur J Cancer; 2013 May 30; 49(7):1654-61. PubMed ID: 23481513
    [Abstract] [Full Text] [Related]

  • 15. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
    Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK.
    Am J Ophthalmol; 2014 Oct 30; 158(4):831-837.e2. PubMed ID: 25036880
    [Abstract] [Full Text] [Related]

  • 16. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
    Martin-Liberal J, Larkin J.
    Future Oncol; 2015 Oct 30; 11(4):579-89. PubMed ID: 25686114
    [Abstract] [Full Text] [Related]

  • 17. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
    Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD.
    Eur J Cancer; 2014 Feb 30; 50(3):611-21. PubMed ID: 24295639
    [Abstract] [Full Text] [Related]

  • 18. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.
    Heakal Y, Kester M, Savage S.
    Ann Pharmacother; 2011 Nov 30; 45(11):1399-405. PubMed ID: 22028422
    [Abstract] [Full Text] [Related]

  • 19. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.
    Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH, Robson S, Makrutzki M, Antic V, Brown MP.
    Eur J Cancer; 2017 Jul 30; 79():176-184. PubMed ID: 28501764
    [Abstract] [Full Text] [Related]

  • 20. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR, De Los Santos JF, Conry RM.
    Melanoma Res; 2015 Jun 30; 25(3):246-51. PubMed ID: 25746037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 423.